Welcome to the e-CCO Library!

search
Search by: 
Year: Category: Sub Type:
OP022: Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in Inflammatory Bowel Diseases: IBD Character study
Year: 2017
Source: ECCO'17 Barcelona
Authors: Kalla R.
Last Modified: Wednesday, 15 March 2017, 2:30 PM by ECCO Administrator
Crohn's disease, Ulcerative colitis, Immunology
Files: 1
OP022: Rapidity of clinical and laboratory improvements following upadacitinib induction treatment: Data from the CELEST study
Year: 2018
Source: ECCO'18 Vienna
Authors: Schreiber Stefan
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP023: A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in Moderately to Severely active Crohn’s Disease (CD)
Year: 2018
Source: ECCO'18 Vienna
Authors: Danese Silvio
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP023: Maintenance of clinical effect in patients with moderate- to-severe Crohn’s Disease treated with filgotinib, a selective JAK1 inhibitor: Exploratory 20-week data analysis of the Phase 2 FITZROY study
Year: 2017
Source: ECCO'17 Barcelona
Authors: Vermeire S.
Last Modified: Wednesday, 15 March 2017, 2:28 PM by ECCO Administrator
Filgotinib
Files: 1
OP024: Childhood-onset Inflammatory Bowel Disease and risk of cancer – a Swedish nationwide cohort study 1964-2014
Year: 2017
Source: ECCO'17 Barcelona
Authors: Olén O.
Last Modified: Wednesday, 15 March 2017, 2:27 PM by ECCO Administrator
IBD and malignancy, Lymphoma, Paediatric
Files: 1
OP024: Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s Disease: The OPERA II study
Year: 2018
Source: ECCO'18 Vienna
Authors: D´Haens Geert R
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP025: Comparative effectiveness of vedolizumab and tumour necrosis factor–antagonist therapy in Crohn’s Disease: A multicentre consortium propensity score–matched analysis
Year: 2018
Source: ECCO'18 Vienna
Authors: Dulai Parambir S
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP025: Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naïve pediatric patients with Crohn’s Disease in clinical practice
Year: 2017
Source: ECCO'17 Barcelona
Authors: Steiner S.
Last Modified: Wednesday, 15 March 2017, 2:24 PM by ECCO Administrator
Crohn's disease, Disease activity Indices, Adalimumab
Files: 1
OP026: Comparative effectiveness of vedolizumab and TNF-antagonist therapy in Ulcerative Colitis: A multicentre consortium propensity score–matched analysis
Year: 2018
Source: ECCO'18 Vienna
Authors: Dulai Parambir S
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP026: Zero diagnostic yield of dysplasia in polyp adjacent biopsies for patients with Inflammatory Bowel Disease
Year: 2017
Source: ECCO'17 Barcelona
Authors: Lahiff C.
Last Modified: Wednesday, 15 March 2017, 2:21 PM by ECCO Administrator
Colonoscopic surveillance, Chromoendoscopy, Colonoscopy, Dysplasia, UC colorectal cancer surveillance
Files: 1
OP027: IL-33/ST2 axis sustains gut mucosal wound healing and cancerogenesis in Colitis-associated colorectal cancer
Year: 2017
Source: ECCO'17 Barcelona
Authors: Lopetuso L.
Last Modified: Wednesday, 15 March 2017, 2:20 PM by ECCO Administrator
Epithelial cell, Fibroblast, Immunology
Files: 1
OP027: SUCNR1 receptor mediates intestinal fibrosis
Year: 2018
Source: ECCO'18 Vienna
Authors: Cosin-Roger Jesus
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP028: Gut specific regulatory T cells – a new frontier for Crohn’s Disease therapy
Year: 2017
Source: ECCO'17 Barcelona
Authors: Goldberg R.
Last Modified: Wednesday, 15 March 2017, 2:18 PM by ECCO Administrator
Immunology, Lymphocyte,T Cell
Files: 1
OP029: Hypoacetylation of histone-3 is a hallmark of intestinal fibrosis in Crohn’s Disease
Year: 2017
Source: ECCO'17 Barcelona
Authors: Lewis A.
Last Modified: Wednesday, 15 March 2017, 2:12 PM by ECCO Administrator
Genetic factors, Fibrosis
Files: 1
OP02: Impact of therapeutic strategies on intestinal resection rate in paediatric Inflammatory Bowel Diseases: A population-based cohort study over a 24-year period (1988-2011)
Year: 2020
Source: ECCO'20 Vienna
Authors: Delphine Ley
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
OP02: The role of PTPN2 SNP in the pathogenesis of fibrosis in Crohn’s Disease
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Chao Li
Created: Tuesday, 28 May 2019, 3:32 PM
Fibrosis, Mesenchymal cell
Files: 1
OP030: Identification of disease-relevant bacterial signatures in gnotobiotic IL-10 deficient mice using fecal samples from IBD patients undergoing hematopoietic stem cell transplantation
Year: 2017
Source: ECCO'17 Barcelona
Authors: Metwaly A.
Last Modified: Wednesday, 15 March 2017, 2:10 PM by ECCO Administrator
Immunology, Microbiota, HSCT
Files: 1
OP031: Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn’s Disease: 12 month data from the PANTS study
Year: 2018
Source: ECCO'18 Vienna
Authors: Kennedy Nicholas A
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP031: Long-term safety and tolerability of oral tofacitinib in patients with Crohn’s Disease: Results from a phase 2 open-label 48-week extension study
Year: 2017
Source: ECCO'17 Barcelona
Authors: Panés J.
Last Modified: Wednesday, 15 March 2017, 2:07 PM by ECCO Administrator
Tofacitinib, Crohn's Disease
Files: 1
OP032: Efficacy and safety of oral tofacitinib as maintenance therapy in patients with Moderate to Severe Ulcerative Colitis: Results from a phase 3 randomised controlled trial
Year: 2017
Source: ECCO'17 Barcelona
Authors: Panés J.
Last Modified: Wednesday, 15 March 2017, 2:06 PM by ECCO Administrator
Tofacitinib, Ulcerative Colitis
Files: 1